Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

Core Viewpoint - The merger between Transcarent and Accolade is progressing, having passed the antitrust waiting period, and is expected to be completed in the second quarter of 2025, pending stockholder approval and other customary conditions [1][2]. Group 1: Merger Details - The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act has expired, marking a significant milestone in the merger process [1]. - The transaction is anticipated to close in the second quarter of 2025, subject to Accolade stockholder approval and satisfaction of customary closing conditions [2]. Group 2: Executive Insights - Glen Tullman, CEO of Transcarent, emphasized the shared vision of both companies to enhance health and care through the integration of Transcarent's AI-powered solutions with Accolade's advocacy and primary care services [3]. - Rajeev Singh, CEO of Accolade, expressed excitement about the merger, highlighting the goal of empowering healthcare consumers with improved tools and technology [3]. Group 3: Company Profiles - Transcarent aims to simplify access to high-quality, affordable health and care, offering generative AI-powered navigation and comprehensive care experiences [5]. - Accolade provides personalized healthcare solutions, combining virtual primary care, mental health services, and expert medical opinions, achieving consumer satisfaction ratings exceeding 90% [7].